This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MDC1 / Mediator of DNA damage checkpoint protein 1 · IHC design guide
Design Immunohistochemistry for MDC1
Plan MDC1 staining in paraffin sections around its general nuclear tissue pattern (HPA tissue IHC). Start with the catalog antibody at 0.5–1 μg/ml (datasheet: A01252-2), then compare nuclear staining across consistently processed sections (standard IHC practice).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MDC1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across diverse tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A01252-2) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01252-2) | |
| Caveat | DNA damage can produce discrete nuclear foci (UniProt) | |
| Regulation | Intensity varies by tissue cell type (HPA tissue IHC) | |
| Isoform / epitope | Four isoforms; confirm antibody epitope coverage (UniProt) |
Section 1
Recommended MDC1 IHC & IF Protocols
The catalog antibody has a datasheet IHC protocol (datasheet: A01252-2). Published MDC1 IHC methods provide three additional examples for tumor and tissue sections (PMC4177045; PMC4446443; PMC4515811).
| Sample | Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A01252-2) |
| Fixation | Image fixative and duration unreported (datasheet A01252-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A01252-2) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01252-2) |
| Primary antibody | Rabbit anti-MDC1, 0.5-1μg/ml (datasheet A01252-2) |
| Primary incubation | Overnight at 4 °C (datasheet A01252-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A01252-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MDC1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 for the catalog antibody (datasheet: A01252-2); the published pressure-cooker and boiling methods do not specify citrate (PMC4177045; PMC4515811).
Section 2
What Is the Expected MDC1 Staining Pattern?
MDC1 should appear in nuclei across many cell types in paraffin sections: HPA describes general nuclear expression and reports high staining in several glandular, hematopoietic, respiratory epithelial and glial cell populations (HPA tissue IHC). It is a chromatin-associated nuclear protein with no transmembrane segment (UniProt Q14676). HPA rates the tissue IHC evidence Enhanced, while noting medium consistency between staining and RNA expression (HPA tissue IHC).
| Nuclear chromogenic staining in adrenal or breast glandular cells, or bone marrow hematopoietic cells. | This matches cell populations scored High by HPA (HPA tissue IHC). Compare signal within identified cells; a High category does not mean every nucleus in the section must stain equally. |
| Predominantly cytoplasmic or membranous staining with little nuclear signal. | That distribution conflicts with MDC1’s nuclear, chromatin-associated location (UniProt Q14676) and HPA’s general nuclear IHC profile (HPA tissue IHC). Treat it as suspect and review antibody specificity and detection controls (general IHC practice). |
| Strong color in a cell population expected to show little MDC1 staining, such as cardiomyocytes. | HPA scores cardiomyocytes Low (HPA tissue IHC). If the color lies outside nuclei or persists in a no-primary control, investigate cross-reactivity or endogenous detection activity before scoring it as MDC1 (general IHC practice). |
| Diffuse color across nuclei, cytoplasm and surrounding tissue, obscuring cell boundaries. | The lack of a distinct nuclear pattern makes specific MDC1 staining difficult to judge against HPA’s nuclear profile (HPA tissue IHC). Check background with a no-primary control, then review blocking, washing and chromogen development (general IHC practice). |
| No nuclear signal in a section containing adrenal glandular cells or bone marrow hematopoietic cells. | Those populations are scored High by HPA (HPA tissue IHC), so an entirely blank result warrants a technical check. HPA’s Enhanced rating supports the reported pattern but does not guarantee staining in every specimen (HPA tissue IHC). |
💡Expected MDC1 appearanceCall the slide positive when identifiable nuclei show chromogenic signal in an HPA High population, such as adrenal glandular cells or bone marrow hematopoietic cells (HPA tissue IHC); predominant cytoplasmic or membranous color is a suspect positive because MDC1 is nuclear (UniProt Q14676).
| Where should the IHC signal be scored? | Score nuclei in identifiable cells: HPA reports general nuclear expression (HPA tissue IHC), consistent with chromatin-associated MDC1 (UniProt Q14676). HPA’s Low categories for alveolar type I cells and cardiomyocytes are useful comparisons, not absolute negative controls (HPA tissue IHC). |
| How much confidence does the HPA validation provide? | The tissue profile is rated Enhanced, and HPA006915 and CAB080116 each have Enhanced IHC status (HPA tissue IHC; HPA antibodies). HPA also reports medium consistency between staining and RNA expression, so assess compartment and controls alongside intensity (HPA tissue IHC). |
| Are DNA damage foci required in routine tissue IHC? | MDC1 can relocalize to discrete nuclear foci after DNA damage through phosphorylated H2AX (UniProt Q14676). HPA describes general nuclear tissue staining (HPA tissue IHC); absence of resolvable foci alone should not overturn an otherwise appropriate nuclear IHC result. |
| What can sequence information tell us about antibody interpretation? | UniProt lists four isoforms, one protein chain spanning residues 1–2089, and no signal peptide, propeptide or transmembrane segment (UniProt Q14676). These facts support intracellular nuclear interpretation but do not identify the catalog antibody’s epitope or establish isoform coverage. |
| What should IF/ICC show? | HPA reports supported nucleoplasm and nuclear-body localization in ICC-IF, with images from A-431, U-251MG, U2OS and SiHa (HPA subcellular). That is a localization cross-check; this section makes no IF/ICC protocol recommendation. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known HPA High cells are blank. | A failed IHC detection step, unsuitable working conditions or a missing positive population can yield an uninformative slide (general IHC practice); HPA lists the relevant cells as High (HPA tissue IHC). | Confirm the cell population is present, run a known-positive section and follow the catalog antibody’s IHC-P procedure for retrieval, dilution and detection; no target-specific fixation sensitivity is established here. |
| Color is mainly cytoplasmic or membranous. | The compartment conflicts with UniProt’s nuclear localization and HPA’s general nuclear IHC pattern (UniProt Q14676; HPA tissue IHC). | Check a no-primary control and the chromogenic detection workflow, then reassess nuclear signal with the counterstain visible (general IHC practice). |
| Low-scored cells appear strongly positive. | Cardiomyocytes and alveolar type I cells are scored Low, although Low does not mean uniformly absent (HPA tissue IHC). Misidentified cells or nonspecific color can distort interpretation (general IHC practice). | Confirm cell identity and nuclear placement; compare with a no-primary control and an HPA High population on a separately validated section (HPA tissue IHC; general IHC practice). |
| Background masks nuclear detail. | Widespread color cannot be reliably assigned to HPA’s reported nuclear MDC1 pattern (HPA tissue IHC). Excess detection signal or inadequate washing can raise background (general IHC practice). | Inspect the no-primary control; review blocking, washes and chromogen development, then score only nuclei that remain distinguishable (general IHC practice). |
| Nuclear staining is present but lacks discrete foci. | UniProt describes foci after DNA damage, while HPA reports general nuclear tissue expression (UniProt Q14676; HPA tissue IHC). | Assess compartment and cell identity against the tissue profile; do not require visible foci to call routine chromogenic IHC positive (HPA tissue IHC; general IHC practice). |
| Two antibodies give different nuclear intensities. | HPA reports Enhanced IHC status for HPA006915 and CAB080116, but the tissue profile has only medium staining-to-RNA consistency (HPA antibodies; HPA tissue IHC). The supplied sources do not resolve epitope or isoform coverage. | Compare matched positive and no-primary controls, then document each antibody’s nuclear pattern separately rather than treating equal intensity as a validation requirement (general IHC practice). |
Experiment evidence
IHC & IF images showing MDC1 staining
A01252-2 · IHCIHC analysis of MDC1 using anti-MDC1 antibody (A01252-2). MDC1 was detected in paraffin-embedded section of human colon cancer tissue. Heat
A01252-2 · IHCIHC analysis of MDC1 using anti-MDC1 antibody (A01252-2). MDC1 was detected in paraffin-embedded section of human lung cancer tissue. Heat m
A01252-2 · IFIF analysis of MDC1 using anti-MDC1 antibody (A01252-2). MDC1 was detected in immunocytochemical section of A431 cells. Enzyme antigen retri
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137337-MDC1/tissue/cerebral+cortex#imid_2296968
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137337-MDC1/tissue/colon#imid_2296902
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137337-MDC1/tissue/liver#imid_2296911
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137337-MDC1/tissue/kidney#imid_2296896
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006915; green = MDC1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006915; green = MDC1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MDC1 IHC & IF
🧪Run breast tissue first and score its glandular cells for MDC1 staining (HPA: High in breast glandular cells). HPA detects MDC1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and expect anucleate erythrocytes, if present on the positive slide, to lack nuclear staining (HPA: no negative tissue rows; UniProt Q14676: nuclear localization).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: MDC1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MDC1 in A-431, U-251MG, U2OS, SiHa, with annotated localisation: Nucleoplasm (supported), Nuclear bodies (supported) (HPA subcellular).
Technical controls: Run a secondary-only slide, a rabbit IgG isotype control matched to the primary antibody’s clonality when known, and an MDC1 knockout specimen where available to test specificity (selected-SKU caption: rabbit primary and goat anti-rabbit secondary). Check endogenous peroxidase activity in breast sections before chromogenic detection, especially around blood cells (HPA: breast glandular cells High; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A01252-2 paraffin-section caption does not state the fixative (selected-SKU tissue-IHC caption). The caption reports heat retrieval in citrate buffer at pH 6 for 20 minutes for colon cancer tissue; this is a starting condition to evaluate, not evidence that retrieval is required in breast tissue (selected-SKU tissue-IHC caption). IF/ICC can help resolve MDC1’s nuclear bodies or damage-associated foci, but the supplied evidence does not establish that frozen sections or IF are easier than paraffin IHC (HPA: supported nucleoplasm and nuclear bodies; UniProt Q14676: nuclear foci after DNA damage).
HPA tissue IHC evidence for MDC1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: MDC1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced MDC1 IHC Tips
Troubleshoot MDC1 staining by checking nuclear localisation, the documented paraffin section workflow, and controls that distinguish DNA damage foci from staining artefacts.
Which retrieval conditions should I try first for MDC1 paraffin sections?
Start with heat mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A01252-2). The documented paraffin section image used that retrieval before overnight incubation at 4°C with 1 µg/ml antibody (datasheet A01252-2). If nuclear staining is weak, compare a modest change in heating time on adjacent sections while holding antibody concentration and detection conditions constant (standard IHC practice). Score nuclear signal alongside tissue morphology, because excessive heating can damage sections and make apparent improvement difficult to interpret (standard IHC practice). Use a reference section in every retrieval run to separate retrieval variation from biological variation (standard IHC practice).
How should I troubleshoot weak staining when fixation details are unknown?
The selected image identifies a paraffin embedded section but does not report its fixative, so MDC1 sensitivity to fixation is unknown (datasheet A01252-2). Record the fixative and fixation duration for each new specimen, then compare sections processed under documented conditions (standard IHC practice). Keep citrate retrieval at pH 6 for 20 minutes as the initial reference condition when testing those specimens (datasheet A01252-2). Examine nuclear detail and tissue integrity before increasing retrieval or antibody concentration, since poor preservation can confound either adjustment (standard IHC practice). Do not attribute differences between specimens to MDC1 biology until processing differences have been assessed (standard IHC practice).
What staining pattern should count as MDC1 in tissue sections?
Prioritise staining within intact nuclei: MDC1 is associated with chromatin, and the tissue IHC profile describes general nuclear expression (UniProt Q14676; HPA tissue IHC). Nuclear bodies and nucleoplasmic signal are also supported by subcellular imaging, while discrete nuclear foci can form after DNA damage through phosphorylated H2AX (HPA subcellular; UniProt Q14676). Compare nuclear staining with a counterstain on the same section and score only cells whose boundaries and nuclei remain interpretable (standard IHC practice). Diffuse cytoplasmic DAB without corresponding nuclear signal should prompt review of background, detection chemistry and morphology before being called MDC1 (UniProt Q14676 localisation; standard IHC practice).
Could isoforms or epitope changes explain inconsistent MDC1 staining?
MDC1 has 4 annotated isoforms and contains an FHA domain and 2 BRCT domains, so epitope placement matters when comparing antibodies (UniProt Q14676). The supplied image caption does not locate the A01252-2 epitope or establish which isoforms it recognises (datasheet A01252-2). MDC1 also has numerous annotated modified residues, but this evidence alone does not show that a particular modification alters this antibody’s staining (UniProt Q14676). Check the antibody’s documented immunogen or epitope before attributing discordant nuclear patterns to isoform selection, and compare matched sections with consistent processing (standard IHC practice). Report any unresolved epitope uncertainty with the scoring results (standard IHC practice).
How can IF help resolve ambiguous MDC1 staining in sections?
Use IF as a separate localisation check, since the selected antibody evidence here documents chromogenic paraffin section staining (datasheet A01252-2). Multiplex MDC1 with a marker identifying the cell population being scored, and include a nuclear counterstain to verify that candidate signal lies inside nuclei (standard IF practice; UniProt Q14676 localisation). Select fluorophores in channels with low measured tissue autofluorescence, using an unstained section and single stain controls to assess bleed through (standard IF practice). Because MDC1 is nuclear and chromatin associated, use permeabilisation sufficient for antibody access to the nucleus while checking that nuclear morphology remains intact (UniProt Q14676; standard IF practice).
What should I check when DAB staining obscures MDC1 nuclei?
The documented workflow used 10% goat serum blocking, a biotinylated secondary antibody and DAB development after citrate retrieval (datasheet A01252-2). Compare a no primary control and an appropriate detection control to identify staining contributed by the detection system (standard IHC practice). Include a peroxidase blocking step when using enzyme based DAB detection, and inspect endogenous pigment or precipitate before changing the MDC1 antibody concentration (standard IHC practice). If background persists, review blocking, wash stringency and development time on matched sections while preserving readable nuclear morphology (standard IHC practice). Count only signal localised to intact nuclei when evaluating a revised condition (UniProt Q14676 localisation; standard IHC practice).
How should I quantify heterogeneous nuclear MDC1 staining? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and tissue regions before examining treatment groups, because the HPA profile describes general nuclear expression across tissues (HPA tissue IHC; standard IHC practice). Record the percentage of positive intact nuclei and, when intensity is reproducible, calculate a nuclear H score from the percentages at each intensity level (standard IHC practice). Normalise counts to the number of evaluable nuclei in the same cell population, or report positive nuclei per mm² of viable tissue with sampling area stated (standard IHC practice). Keep illumination, DAB development, thresholds and region selection consistent, and report excluded necrotic or damaged areas (standard IHC practice).
How do I distinguish true MDC1 signal from artefact?
A credible signal lies in intact nuclei, consistent with MDC1’s chromatin association and the general nuclear tissue profile (UniProt Q14676; HPA tissue IHC). Discrete foci may reflect recruitment to DNA damage sites, but chromogenic foci alone do not establish DNA damage without an independent marker and suitable controls (UniProt Q14676; standard IHC practice). Review staining restricted to section edges, necrotic regions or an unexpected compartment against morphology and no primary controls before scoring it (standard IHC practice). Check endogenous enzyme contribution when DAB deposits appear independently of the primary antibody, and compare the relevant cell population rather than assuming every stained cell has the same identity (standard IHC practice).
Boster reagents
Best MDC1 / Mediator of DNA damage checkpoint protein 1 IHC Antibodies
A01252-2 has IHC images from human paraffin sections of colon cancer, lung cancer and testis, and an IF/ICC image from A431 cells (catalog image captions).
Real IHC data
Anti-MDC1 Antibody
Cat # A01252-2
A01252-2 is listed for human IHC, with images of paraffin sections from colon cancer, lung cancer and testis (catalog applications, reactivity and IHC captions). The same SKU is listed for IF/ICC, with an image from A431 cells (catalog applications and IF caption).
Which to pick: For tissue IHC, choose A01252-2: its images document human paraffin sections, including colon cancer; the fixative is unreported (catalog IHC captions). For IF/ICC, choose A01252-2 based on its A431 cell image; it is rabbit hosted, and clonality is unreported (catalog IF caption and product details). No cross species option is documented because A01252-2 lists only human reactivity (catalog reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q14676 (MDC1_HUMAN, Mediator of DNA damage checkpoint protein 1).
- Human Protein Atlas. MDC1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. MDC1 subcellular location (ICC-IF): Localized to the nucleoplasm and nuclear bodies..
- Human Protein Atlas. MDC1 antibody validation summary (3 antibodies).
- SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Oncogene 2018 — PMC6545484.
- Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathology oncology research : POR 2014 — PMC4177045.
- MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer. Nucleic acids research 2015 — PMC4446443.
- MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression. International journal of biological sciences 2015 — PMC4515811.
- PubMed PMID:8724849 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
- PubMed PMID:16702430 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MDC1 (Mediator of DNA damage checkpoint protein 1). Expected localisation General nuclear tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A01252-2). Validated IHC antibody: A01252-2 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colon cancer tissue; fixative not specified (datasheet A01252-2); 2. Fixation: Image fixative and duration unreported (datasheet A01252-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A01252-2); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01252-2); 8. Primary antibody: Rabbit anti-MDC1, 0.5-1μg/ml (datasheet A01252-2); 9. Primary incubation: Overnight at 4 °C (datasheet A01252-2). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01252-2); Caveat: DNA damage can produce discrete nuclear foci (UniProt); Isoform / epitope: Four isoforms; confirm antibody epitope coverage (UniProt); Regulation: Intensity varies by tissue cell type (HPA tissue IHC). Evidence: UniProt Q14676, HPA tissue IHC · Enhanced, HPA ICC-IF · nucleoplasm and nuclear bodies., Datasheet A01252-2, PMC4177045, PMC4446443. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MDC1/immunohistochemistry-ihc-guide.